论文部分内容阅读
目的 探讨抑癌基因PTEN产物PTEN蛋白在由正常子宫内膜过渡至子宫内膜癌过程中的表达缺失情况及其临床意义。方法 用SP免疫组化法测定 73例子宫内膜癌、 2 5例子宫内膜非典型增生、 71例子宫内膜增殖症和 31例正常子宫内膜组织中PTEN蛋白的表达 ,并与组织学类型、组织学分级、肌层浸润深度和临床分期等生物学行为进行相关分析。结果 PTEN蛋白在子宫内膜腺癌和癌前病变中的表达缺失率分别为 6 6 6 7%和 76 0 0 % ,表达缺失率与组织学类型(P <0 0 0 5 )和组织学分级有关 (P <0 0 5 ) ,与子宫内膜癌肌层浸润深度和临床分期无关 (P >0 0 5 )。结论 PTEN表达缺失是子宫内膜癌发生的早期分子事件 ,PTEN蛋白表达缺失是早期诊断子宫内膜癌及癌前病变较好的生物标志。
Objective To investigate the loss of PTEN protein PTEN expression during the transition from normal endometrium to endometrial carcinoma and its clinical significance. Methods SP immunohistochemical method was used to detect the expression of PTEN protein in 73 cases of endometrial carcinoma, 25 cases of endometrial dysplasia, 71 cases of endometrial hyperplasia and 31 cases of normal endometrium, Type, histological grade, depth of myometrial invasion and clinical stage and other biological behaviors. Results The loss of PTEN protein expression in endometrial adenocarcinoma and precancerous lesions were 66.7% and 76.0%, respectively. The loss of expression was correlated with histological type (P <0.05) and histological grade (P <0.05), but not with the depth of myometrial invasion and clinical stage (P> 0.05). Conclusion The loss of PTEN expression is an early molecular event in endometrial carcinoma. The loss of PTEN protein is a good biomarker for early diagnosis of endometrial carcinoma and precancerous lesions.